Systemic neoadjuvant therapy of luminal breast cancer in 2016

被引：2
|
作者：
Cottu, Paul H. [1 ]
机构：
[1] PSL Res Univ, Inst Curie, Dept Med Oncol, 26 Rue Ulm, F-75005 Paris, France
来源：
BULLETIN DU CANCER | 2017年 / 104卷 / 01期
关键词：
Luminal breast cancer; Neoadjuvant; Endocrine therapy; Chemotherapy; PATHOLOGICAL COMPLETE RESPONSE; ADJUVANT ENDOCRINE THERAPY; RANDOMIZED PHASE-II; POSTMENOPAUSAL PATIENTS; EVALUATING ANASTROZOLE; TRIAL; CHEMOTHERAPY; WOMEN; COMBINATION; LETROZOLE;
D O I：
10.1016/j.bulcan.2016.09.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Neoadjuvant systemic therapies have been extensively evaluated in luminal breast cancer. Conventional cytotoxic chemotherapy increases breast conservation rate, albeit with a low level of complete pathological response of uncertain clinical significance. Endocrine therapies allow similar clinical results with much less side effects. Biological criteria of response to endocrine therapies are still being defined. The neoadjuvant setting must be used for early development of new compounds and to further document biological mechanisms of sensitivity and resistance to treatments.
引用
收藏
页码：69 / 78
页数：10
相关论文
共 50 条
  • [1] Neoadjuvant systemic therapy for breast cancer
    Zaborowski, Alexandra M.
    Wong, Stephanie M.
    [J]. BRITISH JOURNAL OF SURGERY, 2023, 110 (07) : 765 - 772
  • [2] Adjuvant and neoadjuvant systemic therapy for breast cancer
    Schmid, P
    Possinger, K
    [J]. INTERNIST, 2002, 43 (03): : 341 - +
  • [3] Utilization of neoadjuvant systemic therapy (NST) for breast cancer
    Mohiuddin, Jahan J.
    Deal, Allison Mary
    Carey, Lisa A.
    Lund, Jennifer Leigh
    Baker, Brock R.
    Zagar, Timothy M.
    Jones, Ellen
    Marks, Lawrence Bruce
    Chen, Ronald C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Neoadjuvant systemic therapy and the surgical management of breast cancer
    Waljee, Jennifer F.
    Newman, Lisa A.
    [J]. SURGICAL CLINICS OF NORTH AMERICA, 2007, 87 (02) : 399 - +
  • [5] Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties
    van de Wiel, Mick
    Dockx, Yanina
    Van den Wyngaert, Tim
    Stroobants, Sigrid
    Tjalma, Wiebren A. A.
    Huizing, Manon T.
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2017, 210 : 144 - 156
  • [6] Impact of neoadjuvant systemic therapy on sTIL in breast cancer
    Armaghani, Avan
    Asirvatham, Ruth
    Mramba, Lazarus
    Daily, Karen
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [7] Neoadjuvant systemic therapy for breast cancer: the Westmead experience
    Cocco, Annelise M.
    Messer, David
    Brown, Alexander
    Sriram, Nina
    Gilchrist, Jenny
    Al-Mansouri, Loma
    Kefford, Richard
    Meybodi, Farid
    French, James
    Hsu, Jeremy
    Elder, Elisabeth
    [J]. ANZ JOURNAL OF SURGERY, 2018, 88 (06) : 640 - 644
  • [8] Efficacy of neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in luminal A or luminal B breast cancer patients: Does it matter?
    Altundag, Kadri
    [J]. JOURNAL OF BUON, 2019, 24 (06): : 2581 - 2581
  • [9] SABCS 2016: systemic therapy for metastatic breast cancer
    Gampenrieder S.P.
    Rinnerthaler G.
    Greil R.
    [J]. memo - Magazine of European Medical Oncology, 2017, 10 (2) : 86 - 89
  • [10] Neoadjuvant systemic therapy in invasive lobular breast cancer: Is it indicated?
    Tsung, Karen
    Grobmyer, Stephen R.
    Tu, Chao
    Abraham, Jame
    Budd, G. Thomas
    Valente, Stephanie A.
    [J]. AMERICAN JOURNAL OF SURGERY, 2018, 215 (03): : 509 - 512
12345